Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer

Trial Profile

Multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jan 2019

At a glance

  • Drugs Pertuzumab (Primary) ; Trastuzumab (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms TRIUMPH study
  • Most Recent Events

    • 27 Dec 2018 Planned number of patients changed from 36 to 50.
    • 21 Dec 2017 Status changed from not yet recruiting to recruiting.
    • 03 Oct 2017 Planned initiation date changed from 1 Oct 2017 to 16 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top